P1‐256: Ribosomal Genes Activity, Apolipoprotein‐E and Interleukin‐6 Polymorphisms in Alzheimer's Disease

plasma drug level (2.5 hours). The study design had two independent variables: TOMM40 gene (short vs long; between-subjects) and drug administration (placebo vs 0.5 mg vs 1 mg; within-subjects). We measured the difference from baseline in total recall. Results: We conducted a 2 X 3 repeated-measures ANOVA and observed an interaction between drug administration and TOMM40 (p 1⁄4 .022). Pairwise comparisons indicated that poly-T length did not influence memory performance when placebowas administered, but was associated with worse recall when lorazepam was administered, both for 0.5 mg (p 1⁄4 .004) and 1.0 mg (p 1⁄4 .001) doses. Conclusions: Our pilot data suggest that variants of TOMM40 may serve as pharmacodynamic predictors of drug-induced memory dysfunction in e4 negative individuals, most of whom had the e3/e3 genotype. Given that the frequency of e3/e3 in the general population is over 55%, this biomarker could have important clinical implications.